The phosphodiester hexadeoxyribonucleotide R-95288 is a potent anti-human immunodeficiencr virus type 1 (HIV-1) agent in vitro which consists a a TGGGAG nucleoside sequence with dibenzyloxybenzyl and hydroxyethyl substituents at the 5'-and 3'-ends, respectively. In this study, the antiviral activity of R-95288 against various strains of HIV-1 in vitro was assessed and its mechanism of action was analysed. R-95288 inhibited replication of all strains of HIV-1 used including laboratory strains with the syncytium-inducing (51) phenotype and clinical isolates with both 51 and non-51 (NSI) phenotypes. The 50% inhibitory concentrations (lC 5 s) were 0.62-18~tg ml." (0.21-6.2~tM). R-95288 inhigited the binding and fusion of HIV-1-infected T cells with CD4+ cells. In addition, R-95288 specifically blocked the binding of monoclonal antibodies, recognizing the anti-V3 loop or the CD4-binding site of the virus envelope glycoprotein gp 120. Furthermore, the target site of R-95288 within the V3 loop was found in the putative heparin-binding region by binding inhibition assays using various anti-V3 loop antibodies. These results suggest that R-95288 can inhibit various strains of HIV-1, possibly by specific interaction with gp 120.
Introduction
The current trend in chemotherapy for human immunodeficiency virus type 1 (HIV-1) infection is the use of different drugs in combination since resistant variants easily develop after treatment with an anti-HIV-1 drug as monotherapy (Larder et al., 1989; St Clair et al., 1991) . Although inhibitors of viral reverse transcriptase and protease are now available and clinically used in combination therapy, which has proven to produce a better therapeutic effect in vivo (Vella, 1995; Hammer, 1996) as well as in vitro (Lambert et al., 1993) , no drug that inhibits HIV-1 replication by any mechanisms besides inhibition of reverse transcriptase and protease is in clinical use. Providing such a novel antiviral drug, which could prove to be a good combination partner, is therefore desirable. Inhibitors of virus adsorption or entry to susceptible cells are possible candidates. However, the poor bioavailability, unexpected tissue distribution and side-effects, including anticoagulant activity, often discourage further clinical development of these inhibitors, as described for polysulphates (Dawes et al., 1986; Lorentzen et al., 1989; Flexner et al., 1991) .
A number of oligonucleotide compounds have been reported to be potent anti-HIV-1 agents in vitro. One widely understood mode of action of such oligonucleotides is inhibition of gene expression by blocking the translation process as antisense molecules (Dash et al., 1987) . However, other mechanisms have also been found including the inhibition of virus integrase activity and of interaction of envelope glycoprotein gp120 with its receptor CD4 (Stein et al., 1991 (Stein et al., , 1993 Ojwang et al., 1995; Wyatt et al., 1994; Buckheit et al., 1994) . For example, oligonucleotides with phosphorothioate linkages, a cytidine homopolymer (28-mer), S-dC28 (Stein et al., 1991 (Stein et al., , 1993 and a guanine-rich oligonucleotide (8-mer), ISIS5320 (Wyatt etal., 1994; Lederman et al., 1996) , were found to inhibit HIV-1 replication by interaction with CD4 and/or the V3loop of gp120. Moreover, guanine-rich oligonucleotides with only phosphodiester linkages were also found to exhibit anti-HIV-1 activity by interference with the receptor function of gp120 if covalently linked to a hydrophobic substituent at the 5'-end (Furukawa et al., 1994; Agatsuma et al., 1996) . The essential nucleoside sequence TGGGAG was determined by analysis of the structure-activity relationships of the lead sequence motifs previously reported . On the basis of this knowledge, hexaoligonucleotide R-95288, which consists of the same nucleoside sequence with dibenzyloxybenzyl and hydroxyethyl groups at the 5'-and 3'-ends to protect from exonuclease activity, was identified as the shortest anti-HIV-1 oligonucleotide in vitro with favourable stability in serum and pharmacokinetic profiles in vivo (Koga et al., 1996; M Koizumi et al., unpublished results; Fig. 1) . It was recently reported that R-95288 can form a parallel intermolecular tetramer structure and tetramer formation seems to be necessary for the anti-HIV-1 activity (Watanabe et al., 1996) . The nucleoside linkages of R-95288 are natural phosphodiester bonds and, therefore, have no chirality. Moreover, R-95288 can achieve sufficient plasma concentration in mice . The structural originality and metabolic advantages prompted us to examine further the anti-HIV-1 activity of the short phosphodiester oligonucleotide in vitro against different laboratory strains and clinical isolates of HIV-1 in human peripheral blood mononuclear cells (PBMC). The mechanism of its anti-HIV-1 activity was also investigated.
Materials and Experimental Procedures
Compounds R-95288 [molecular weight (MW) 2905.83] was synthesized as reported previously (Koga et al., 1996; M Koizumi et al., unpublished results) . Heparin derived from porcine intestinal mucosa (MW 6000) was obtained from Sigma. Dextran sulphate (MW 8000) and 3'-azido-3'-deoxythymidine (zidovudine;AZT) was also obtained from Sigma.
Cells and viruses
Human T cell lines H9, C8166, MT-2, MT-4, H938 and the B cell line 1M were obtained from the MRC AIDS Directed Programme (MRC ADP; NIESC, Potters Bar, UK) and were maintained in RPMI 1640 (Gibco BRL) supplemented with 10% fetal calf serum (FCS; Gibco BRL), 1 mM glutamine, 100 U mL-l penicillin and 100 tg mL-l streptomycin. Human PBMC were prepared from acid citrate glucose-treated buffy coat (North London Blood Transfusion Centre, London, UK) by Lymphoprep (Nycomed, Oslo, Norway). A CD4+enriched cell population was achieved by anti-CD8 antibody-coupled magnetic beads (M450; Dynal) according to the manufacturer's recommendation. For antiviral assays, PBMCs were stimulated for 3 days prior to infection with 10~g mL-l phytohaemagglutinin (PHA) and 10 U mL-l of human recombinant interleukin 2 (IL-2; Boehringer Mannheim). Laboratory strains of HIV-1 including HIV-1 HXB 2 and HIV-1 RF were obtained from the MRC ADP and were grown in MT-4 cells to obtain the virus stocks, which were stored in liquid nitrogen. A HIV-1 clinical isolate, HIV-1 c C1 ' was kindly provided by DL Taylor (MRC Collaborative Centre, London, UK). Other clinical isolates of HIV-1 were obtained after coculture of PBMCs from patients with AIDS (provided by AS Tyms, MRC Collaborative Centre) with uninfected stimulated PBMCs. H9 cells chronically infected with HIV-1 HXB2 (H9/HXB2) were generated after transfection with pHXB2D (MRC ADP). HIV-1 c c 1 -' HIV-1 RF -and HIV-1 BBB-infected H9 cells (H9/CC1, H9/RF and H9/BBB) were obtained after infection of H9 cells with the virus stocks of HIV-1 CC l' HIV-1 RF and HIV-1 BBB , respectively. These chronically infected cells were finally generated by cultivation for more than 4 weeks after transfection or infection. The infected H9 cells induced by this method expressed no CD4 on the cell surface, as determined by flow cytometric analysis.
Antibodies
The sources, specificities and isotypes of the anti-gp120 monoclonal antibodies (MAbs) employed are shown in Table 1 . Antibody 2F5 (anti-gp41; amino acids 662-667 of BH10; human IgG3) (Muster et al., 1993) was purchased from Waldheim Pharmazeutika (Vienna, Austria). BAS (anti-human CD26; mouse IgG2a) was from Binding Site (Birmingham, UK). The following antibodies were obtained from Becton Dickinson: Leu3a , 1985) was used to number the amino acids of the epitopes.
(anti-human CD4; mouse IgG1), LB2 (anti-human CD54; mouse IgG2b), G25-2 (anti-human CDlla; mouse IgG2a), L130 (anti-human CD18; mouse IgG1) and L178 (anti-human CD44; mouse IgG1). Each isotype control was from PharMingen (San Diego, Calif, USA). Peroxidase-conjugated secondary antibodies (goat anti-mouse IgG and goat anti-rat IgG) and dichlorotriazinyl amino fluorescein (DTAF)-conjugated secondary antibodies (goat anti-mouse IgG, goat antirat IgG and goat anti-human IgG) were from Bio-Rad (Hercules, Calif, USA) and Pierce (Rockford, Ill., USA), respectively.
Antiviral assays
The antiviral activity of the compounds in MT-4 cells infected with the laboratory strains ofHIV-1 (HIV-1 HXB 2 or HIV-1 RF ) was determined by the tetrazolium reduction (MTT) cell viability assay as described previously (Pauwels et al., 1988) . Briefly, 10 7 MT-4 cells were infected with about 2x10 s 50% tissue culture infectious doses (TCID so) of a HIV-1 virus stock solution. Mter washing twice with medium, the infected cells (5x10 4 200~LL-l well") were distributed to wells in 96-well plates in the presence or absence of different concentrations of R-95288. For the assessment of antiviral activity against clinical isolates of HIV-1, infected PBMCs were mixed with PHA-and IL-2-stimulated uninfected PBMCs in a 1 : 10 ratio and were cultured on 96-well cell culture plates in the presence or absence of various concentrations of a test compound.
Mter 3 days the cell-free supernatant was assayed for levels of HIV-1 p24 antigen by a commercially available ELISA kit (Coulter, Miami, Fla., USA). The syncytiuminducing (SI) or non-Sl (NSI) phenotype of the viruses was determined in parallel with the antiviral assay by Antiviral Chemistry& Chemotherapy 8(5) coculture of infected PBMCs with MT-2 cells. The cells were observed for the presence of syncytia, as described previously (Koot et al., 1992) .
Cell fusion assay
(i) Quantification by chloramphenicol acetyl transferase (CAT) reporter gene system. HIV-1-mediated cell fusion was performed by coculture of 2x10 s H9/BBB cells with 2x10 s H938 indicator cells, containing the HIV-1 long terminal repeat (LTR) gene linked to the CAT gene (Felber & Pavlakis, 1988) , in the presence or absence of different concentrations ofR-95288 at 3TC for 24 h. The cells were collected and lysed and the amount of CAT protein was measured by a commercial ELISA kit (Boehringer Mannheim). In this sytem, membrane fusion correlates with Tat protein-dependent LTR transcriptional activation and, therefore, cell-to-cell fusion can be quantified by the detection of CAT protein.
(ii) Quantification ofsyncytium formation under a microscope. HIV-1 chronically infected H9 cells (2.5x10 4 well.") and C8166 cells (7.5x10 4 well") were distributed in triplicate on a 96-well plate in the presence of serial twofold dilutions ofR-95288. The cells were incubated at 3TC for 18 h and then syncytia (three times the diameter of normal cells) were counted under a microscope and the concentrations ofR-95288 in the wells in which 50% reduction of the number of syncytia were observed, was determined.
Cell binding assay
JM cells (CD4+ CD8+; 2x10 6 ) were incubated with H91HXB2 cells (1x10 6 ) in the presence ofvarious concentrations ofR-95288 for 1.5 h at 3TC. FreeJM cells andJM cells bound to H91HXB2 cellswere collected byanti-CD8 antibody-coupled magnetic beads (M450; Dynal). The cell-bead complex was washed with RPMI 1640 medium containing 10% FCS. Then the captured H91HXB2 cells were quantified by measuring the level of p24 in the cell lysate using a commercial p24 ELISA kit (Coulter).
Antibody binding assay
(i) Detection ifthe antibody binding to immobilized gp120, V3peptide or H~l-inftcted H9 cells. Binding ofMAbs to recombinant gp120 uIB (Intracel, Cambridge, Mass., USA), V3 peptide (amino acids 297-319 of gp120 uIB ; TRPNNNTRKSIRIQRGPGRAFVT; Intracel) or H9/HXB2 cells was performed and analysed as described elsewhere (Agatsuma et al., 1996) .
(ii) Analysis ifthe target site ifR-95288 within the V3 loop by capture ELISA. Capture antibody D7324 (Aalto, Dublin, Ireland) was adsorbed onto a 96-well plate (Sterilin 612U96) by incubation at 4°C overnight at a concentration of 10 IJ,g mL-1 in 100 IJ,L of 0.1 M Tris-HCl pH 9.6. The wells were washed three times with PBS containing 0.05% Tween 20 and then blocked for 2 h at room temperature with 200~tL of PBS containing 1% BSA (Sigma). Recombinant gp120 (200 ng mL-l; Intracel) was bound to D7324 by incubation in 100 L of PBS containing 1% ESA and 1% normal sheep serum at room temperature for 2 h. After washing the wells five times with 0.05% Tween 20-PBS, anti-V3 loop MAbs were added in triplicate to PBS containing 1% BSA and 1% normal sheep serum in the presence of different concentrations of R-95288. The wells were incubated at room temperature for 30 min. Unbound antibody was removed by washing five times with 0.05% Tween 20-PES. Bound antibody was detected by peroxidase-conjugated goat anti-mouse IgG or goat antirat IgG (Bio-Rad) and 3,3',5,5'-tetramethylbenzidine (TMB) solution using TMB ELISA (Gibco BRL). The concentration of the first antibody resulted in an A 4so of 1.0-1.5 as determined by titration. The specificity of the binding of the antibodies used in this study was confirmed by isotype control antibodies.
Results
culture supernatants for the clinical isolates. In this system, the IC so values of AZT, dextran sulphate (MW 8000) and heparin for HIV-1 HXB 2 were 13 nM, 2.9 IJ,g mL-1 (0.36 tM) and 6.0 IJ,g mL-1 (1.0 IJ,M), respectively(means ofthe results from two different experiments, data not shown). R-95288 inhibited the replication of all strains of HIV-1 used in this study as shown in Table 1 . The IC so values were 0.62-18~tg mL-1 (0.21-6.2 !J,M). These results suggest that R-95288 is effective against various strains of HIV-1 with different characteristics. We also found that the susceptibilities of SI strains to R-95288 were markedly varied. HIV-1 HXB2 showed the highest susceptibility to R-95288 in this study. The IC so was 0.62±0.27 IJ,g mL-1 (0.21±0.09 IJ,M). On the other hand, HIV-1 RF showed the lowest susceptibility to R-95288, with an IC so of 18±5 IJ,g mL-1 (6.2±1.7~tM), which was 29-fold greater than that of HIV-1 HXB 2 . In addition, three out of four clinical isolates with the SI phenotype (HIV-1 nnn, HIV-1 zzz and HIV-1 CC1) showed high susceptibility to R-95288 with IC so values of 1.2-2.0 IJ,g mL-1 (0.41-0.69 !J,M), while the other SI clinical isolate, HIV-1 yyy was relativelylow in susceptibilitywith an IC so of7.2±2.3 IJ,g mL-1 (2.5±0.8 IJ,M). The different susceptibilities, therefore, are considered to be irrespective of the source of the virus or the type of assay system used. On the other hand, all four NSI strains showed intermediate susceptibilities to R-95288 with IC so values of3.4-6.3 IJ,g mL-1 (1.2-2.2 !J,M; Table 1) ,Thus, the antiviral activity of R-95288 appeared to be different against each strain of HIV-I.
R~95288 inhibits HIV-l-induced cell-to-cell fusion
The inhibition of HIV-1-induced cell-to-cell fusion was H938 cells were cocultured with H9/BBB cells for 24 h. Cell Iysates were prepared and amounts of CAT protein (indicating cell fusion) were determined by ELISA. The amount of CAT protein obtained from coculture of H9/BBB with H938 cells or from H938 cell culture only in the absence of R-95288 was used as a control (100% or 0% fusion).
Antiviral activity against different laboratoryadapted and clinically isolated strains of HIV-l
We first assessed the antiviral activity of R-95288 against various strains of HIV-1 including laboratory strains with the SI phenotype and clinicalisolateswith both SI and NSI phenotypes in oitro. The antiviral activity of R-95288 was analysed by an MIT cell viability test for the laboratoryadapted strains and by detection of p24 viral antigen in r R-95288, a potent inhibitor of HIV-l 
R-95288 inhibits binding of HIV-1-infected cells to CD4+ cells
The binding of CD4+ cells and HIV-1-infected cells expressing gp120 is an essential step in HIV-1-induced syncytium formation. To determine whether CD4/gp120mediated cell binding could be blocked by R-95288, a cell binding assay was done in the presence of different concentrations of R-95288. H9/HXB2 cells bound to CD4+ CD8+ JM cells were collected by anti-CD8 MAbcoupled magnetic beads and quantified by the presence of p24 viral antigen associated with the bead-cell complexes. Inhibition of cell binding could be measured by the reduction in the amount of p24 viral antigen coupled with the beads in this assay. R-95288 reduced the amount of p24 associated with the beads in a dose-dependent manner, suggesting that R-95288 inhibits the binding of HIV-1infected cells with CD4+ cells (Fig. 3) .
aAnti-HIV-l activity for laboratory-adapted strains and for clinical isolates of HIV-l were determined by MIT cell viability test and by inhibition of p24 production, respectively. The data are indicated as the mean IC 50±SDs. bSyncytiumformation assay was performed by coculturing HIV-l-infected H9 cells with C8166 cells as described in Materials and Experimental Procedures. The data are indicated as the mean IC 50 obtained from two different experiments. eND, not done.
R-95288 interferes with both the V3 loop and the CD4-binding site on gp 120
Since the V3 loop of gp120 is generally believed to be another possible target for inhibitors of HIV-1-mediated cell fusion (Schols et al., 1990) , the ability of R-95288 to interfere with the binding of anti-V3 MAbs was examined. Gp120 immobilized on a polystyrene plate was reacted with anti-V3 MAb u70 or 1l/75a, directed against amino acids 302-319 and a conformational epitope of the 125 Figure 3 . Inhibition ofbinding of HIV-l-infected cells and CD4+ cells by R-95288.
H9/HXB2 cells and JM cells were mixed and incubated For I .5 h at 3rc. FreeJM cells and JM cells bound to H9/HXB2 cells were collected by anti-C08-coated beads and the bead-associated viral antigen p24 was measured by ELISA. The absorbance obtained From the cell culture in the absence of R-95288 was used as a control (100% binding). measured first by the CAT reporter system (Fig. 2) . In this assay, the indicator cell line H938, carrying the HIV-1 LTR gene linked to the CAT gene (Felber & Palvakis, 1988) , and HIV-1 BBB-infected H9 cells (H9/BBB cells) were used. Cocultivation of these two cell lines promotes membrane fusion and resulted in production of CAT protein. Cell-to-cell fusion, therefore, can be scored by the amount of CAT protein in this assay. As shown in Fig. 2 , addition of R-95288 inhibited production of CAT protein in a dose-dependent manner with an IC so of 1.0 [lg mL-l (0.34 [lM) , suggesting that R-95288 inhibits HIV-1-induced cell fusion. We also assessed the inhibition of syncytium formation induced by different strains of HIV-1 by addition of R-95288. Syncytium formation was promoted by coculture of the CD4+ T cell line C8166 with H9 cells chronically infected with three different SI strains of HIV-1, HIV-1 HXB 2 , HIV-1 c c 1 and HIV-1 RF , and was measured under the microscope (Table 2 ). In accordance with the results of the antiviral assay described above, a lower susceptibility ofHIV-1 RF to R-95288 was observed in the inhibition of syncytium formation (IC so 6.3 [lg mL-l; 2.2 [lM) and the IC so values were about 11-22-fold greater than that of HIV-1 HXB 2 (IC so 0.29 [lg mL-l; 0.10 [lM) or HIV-1 c Cl (IC so 0.59 [lg mL-l; 0.20~tM). V3loop, respectively. The binding of both anti-V3 MAbs was markedly inhibited by R-95288 as determined by ELISA (Fig. 4a) . The inhibition was dose-dependent with an IC so of 45~tg mL-l and 23 ug mL-\ respectively. In contrast, a concentration of up to 400~Lg mL-l R-95288 failed to inhibit the binding of two MAbs recognizing the N-terminal region of gp120 (ABi13-106 recognizing amino acids 54-127; ABi13-107 recognizing amino acids 91-149) to recombinant gp120 in the same system. The binding of the anti-CD4 binding site MAb, 39.3b, to gp120 was partially inhibited by addition of 400~Lg mL-l R-95288. The inhibition of the binding was 48%. Moreover, the binding of a70 to V3 peptide immobilized on a plate was also analysed to assess whether R-95288 could directly interact with the V3 loop. In this assay, the binding of a70 was markedly blocked by R-95288 with an rc., of 1.6~tg mL-l (0.55 M) (Fig.4b) .
To examine the effect ofR-95288 on the native gp120, the binding of MAbs was also investigated using chronically HIV-l-infected H9/HXB2 cells. As shown in Fig. 5(a) , the binding of 11/75a to H9/HXB2 cells was markedly inhibited, as measured by flow cytometric analysis.The inhibition was dose-dependent with an IC so of2.0
Lg mL-l (0.69~LM). In addition, the binding of anti-CD4 binding site MAbs 39.3b and 38.1a was markedly inhibited by addition of 100~tg mL-l of R-95288 (Fig. 5b) . The inhibition of the binding was 85% (38.1a) and 86% (39.3b). This observation was consistent with the result that R-95288 blocked CD4/gp120-mediated cell binding as shown in Fig. 3 . In contrast, no inhibition was observed with antibodies that recognize other viral and cellular membrane proteins involved in virus binding, entry and cell fusion: gp41 (Muster et al., 1993) , CD4 (Dalgleish et al., 1984) , CD26 (Callebaut et al., 1993) , CDlla, CD18 and CD54 (Hildreth & Orentas, 1989; Valentin et al., 1990; Gruber et al, 1991; Fecondo et al, 1993) . These observations strongly suggest that R-95288 specifically interferes with the V3 loop as well as the CD4 binding site of gp120 with no apparent interaction with other cell surface molecules that mediate virus-cell interaction.
Analysis of the target site of R-95288 within the V3100p
To obtain further information about the target site of R-95288 within the V3 loop, inhibition of the binding of various anti-V3 MAbs recognizing different epitopes on the V3loop by R-95288 was analysed. Gp120 captured by an anti-gp120 serum-coated well was reacted with various anti-V3 MAbs. Significant inhibition of the binding of 8/38, ABi13-105 and a70 was observed with IC so of less than 4.0~Lg mL-l (1.4~LM; Table 3 ). The recognition epitope of these MAbs contains an amino acid sequence (RKSIR) consisting of basic amino acids, as indicated in Table 3 . In contrast, the binding of NEA9305, which recognizes peptide RlQRGPGRAFVTIGK, was less affected by R-95288 (IC so 36±2~Lg mL-\ 12±0.7~LM). Moreover, no inhibition of the binding of MAb IIIB-V3-13, recognizing peptide IRIQRGPGR, was observed even if 200 !!g mL-l of R-95288 was added, although IIIB-V3-13 can produce strong neutralization against HIV-l infection in vitro (Laman et al., 1992) . These results strongly suggest that the basic region, RKSIR, not IRIQRGPGR, is targeted by R-95288. In this assay, the binding ofIIIB-V3-21 was not specific to gp120 because the binding signal was obtained from wells that were not coated with gp120, and the binding of IIIB-V3-21 was also less affected by R-95288 (IC so 130±10 !!g mL-\ 45±3 !!M). This inhibition profile of R-95288 is quite similar to that of heparin, a putative V3 inhibitor (Harrop et al., 1994; Javaherian et al., 1994) ; binding of MAbs recognizing RKSIR was strongly blocked when a similar analysis was performed on heparin, while the binding of other MAbs was less inhibited or not inhibited at all (Table 3) .
Discussion
It has been demonstrated that R-95288 has antiviral activity against all laboratory strains and clinical isolates of HIV-l tested in vitro, with an IC so of less than 18 !!g mL-l (6.2~IM). In contrast, toxicity ofR-95288 to MT-4 cells was not observed up to at least 1600 !!g mL'" (550 . In conclusion, R-95288 exhibited antiviral activity against various strains of HIV-l at a concentration where no toxicity towards human lymphocytes was observed. The data also demonstrate that R-95288 inhibits the binding of MAbs directed against the V3 region as well as the CD4 binding site on gp120. Inhibition of the binding of the anti-V3 MAb 11175a and the anti-CD4 binding site MAb 39.3b was assessed using two different systems. One was an ELISA using recombinant gp120 and the other was a flow cytometric analysis,where HIV-l-infected cells expressing native gp120 associated to gp41 viral trans-membrane glycoprotein were used. These analyses might reveal the ability of R-95288 to inhibit binding of the MAbs to monomeric gp120 and native oligomeric gp120. We found that R-95288 inhibited the binding of 11175a to the native gp120 at lower concentrations than that to the recombinant gp120. Moreover, 400~lg mL-l (140~IM) of R-95288 inhibited only 48% of the binding of 39.3b to monomeric gp120 while over 80% inhibition by 100 !!g mL-l (34 !!M) ofR-95288 of the binding of the same MAb to native gp120 was observed. These results suggest that R-95288 preferentially interacts with bThe binding of this antibody was not specific for gp 120 in this system. oligomeric native gp120, which is functional in HIV-1 infection, rather than monomeric gp120.
Taken together, the MAb binding assay shows thatR-95288 can interact with two different domains of gp120. The IC so values for R-95288 in inhibiting the binding of an anti-V3 MAb (11/75a; 2.0~lg mL-\ 0.69~lM) ( Fig.  Sa) and anti-CD4 binding MAbs (38.1a, 3.8~g mL-\ 1.3 lM; 39.3b, 3.5~lg mL-\ 1.2~lM; data not shown) as determined by flow cytometric analysis were greater than that for anti-HIV-1 activity (0.62±0.27~lg mL'"; 0.21±0.09~lM) ( Table 2) . It is therefore likely that the dual mechanisms of action could synergistically contribute to the blocking of HIV-1 infection. Interaction of R-95288 with the V3 loop seems to be an electrostatic attraction because all anti-V3 MAbs which competed with R-95288 recognized a basic amino acid sequence, RKSIR, rather than GPGRAF as the principal neutralizing domain for antibodies in gp120 ofHIV-1 IIIB (Javaherian et al., 1990; Ohno et al., 1991) . Recent reports suggest that heparin binds to the consensus amino acid sequence BBXB, BBXXB orBBXXXB (B, basic amino acid; X, non-basic amino acid; Cardin & Weintraub, 1989) and interacts with the RKSIR amino acid sequence of V3 peptide (Javaherian et al., 1994) . The results obtained for heparin in our MAb binding assay were consistent with these reports and the similarity of the target of heparin indicates that R-95288 interacts with a similar portion of the V3 loop. Tetramer formation of the guanosine cluster appears to be essential for its anti-HIV-1 activity (Watanabe et al., 1996) and the higher structure could promote the affinity of R-95288 to the target. The precise determination of the mechanism of interaction of R-95288 with its targets is now underway.
The results also demonstrate that there are some variants with an S1 phenotype showing significantly lower susceptibilities to R-95288 in comparison with other SI variants. This indicates that there are certain amino acid substitutions in the V3 loop which determine the suscep-436 tibilities to R-95288 without affecting the cell tropism. This explanation may be most likely because the V3 loop of HIV-1 RF , the least susceptible strain, contains the heparin binding consensus sequence BBXXXB (RKSITK), which is different from that of HIV-1 HXB 2 , BBXB (KRIR), in the expected site. The difference in the heparin binding consensus among the HIV-1 variants might be a critical factor in the determination of the susceptibility to R-95288 rather than the NSI/SI phenotype. Alternatively, another important region which is involved in the determination of the susceptibility to R-95288 may exist. It would be interesting in the future to examine the relationship between the amino acid sequence of gp120 and drug susceptibilities. The generation and characterization of resistant variants may provide useful information.
In conclusion, the bioavailable short oligonucleotide R-95288 exhibits antiviral activity against various laboratory strains and clinical isolates of HIV-1 in vitro, possibly by specific interaction with the two functional domains of gp120. In addition, in vivo efficiency was recently shown in the hu-PBL-SCID mouse model of HIV-1 infection . These findings indicate that R-95288 may be one of a novel class of chemotherapeutic agents for HIV-1 infection.
